Healthcare
Serina Therapeutics, Inc.(SER)
Live Price
Offline$1.84
+1.66% today
1Y Change
-63.20%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $20.00M
- Revenue Growth
- +132.1%
- EPS Growth
- -26.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Serina Therapeutics, Inc. (SER) is a Healthcare stock with a market cap of $20.00M and listed on AMEX. The stock last traded around $1.84 and down 63.2% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +132.1%, EPS growth of -26.5%, a dividend yield of 0.0%. What stands out right now is revenue +132.1%, EPS -26.5%, free cash flow -4.6% with operating margin -18478.5% and ROIC -709.0%. Valuation already assumes a fairly strong business story at price/sales 139.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SER price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+132.1% vs +7.6% peer median
Operating Margin
Below sector median
-18478.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 19, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +132.1% and EPS is at -26.5%, with operating margin around -18478.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 19, 2026 | โ | +5.6% | +11.8% | +23.0% |
2026 Mar 25, 2026 | +38.0% | -13.9% | -30.0% | -36.0% |
2025 Nov 13, 2025 | +4.3% | +4.3% | -4.1% | -20.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SER
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SER Max Drawdown
-79.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SER and SPY.
Company Overview
Serina Therapeutics, Inc.
New York Stock Exchange American
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
- Leadership
- Steven A. Ledger
- IPO Date
- Jan 21, 2000
- Employees
- 12
- Street Address
- 601 Genome Way
- Mailing
- Huntsville, AL, 35806
- Region
- Huntsville, AL, US
- Reporting Currency
- USD
- Investor Line
- 256 327 9630
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 139.8
- Price/Book
- โ
Growth
- Revenue
- +132.1%
- EPS
- -26.5%
- Free Cash Flow
- -4.6%
Profitability
- Gross Margin
- 43.8%
- Operating Margin
- -18478.5%
- Net Margin
- -14755.4%
- ROE
- -1468.2%
- ROIC
- -709.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.71
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.